Breaking News on Contract Research, Manufacturing & Clinical Trials

Hot Topics > Globalisation



When national businesses become global operations… With the industry sourcing more raw materials and services from around the world and distributing its products in new markets, companies are adapting their business processes to suit a more complex global operating environment.

INC Research expands in Japan amid 'evolution of the clinical trial landscape'

30-May-2016 - The CRO has opened new offices in Japan as part of its long-term growth strategy in the country – the world’s second largest pharmaceutical market.

ClinTec 'on track' with growth strategy as new offices open in Spain

26-May-2016 - ClinTec International has opened two new offices in Spain as it prepares for an expanding local clinical trial portfolio and larger outsourcing engagements in the country.

Famar set to step into North America by buying Quebec plant from Bayer

18-Apr-2016 - European CDMO Famar says it will continue making products on behalf of Bayer after acquiring a Canadian manufacturing facility from the firm.

Mexico office to bolster CRO Eurotrials' presence in Latin America

17-Mar-2016 - Eurotrials has opened an office in Mexico City in a bid the dominant CRO in the growing Mexican clinical research market.

Eurofins expands into Asia-Pacific through QC services firm acquisition

14-Mar-2016 - Eurofins has bought Australian QC firm ams Laboratories in a push to expand its biopharma testing services into the Asia-Pacific region.

Catalent bringing clinical supply services to Japanese facility

21-Jan-2016 - Catalent will expand its cGMP facility in Japan to bring secondary packaging and clinical supply services to the region.

Exclusive interview

India has 'natural potential to grow' in CRO space, says Syngene CEO

14-Jan-2016 - India’s CRO industry is playing catch-up to the generic and manufacturing sectors, according to the departing CEO of one of the largest players, Syngene.

PRA and newly private WuXi call time on China JV

11-Dec-2015 - WuXi PharmaTech and PRA Health Sciences have ended a three year clinical trial management partnership in China.

Megamerger Pfall-out? $160bn Pfizer-Allergan deal to hit CROs in short-term, analysts

24-Nov-2015 - The $160bn Pfizer-Allergan megamerger could lead to booking cancellations in the short-term say analysts, but CROs – especially Icon, Parexel and PPD - should ultimately benefit.

Recipharm reports 55% sales growth; North America next step in M&A strategy

05-Nov-2015 - Gaining a foothold in North America would complete Recipharm’s growth strategy in becoming a global CDMO leader, the firm says.

PRA assessing 'underperforming' JV in light of WuXi going private

04-Nov-2015 - Three years on, a joint venture with WuXi Pharmatech is underperforming according to PRA management and could be renegotiated when WuXi goes private.

CROs engaging in a ‘war on talent’, Quintiles CEO says

30-Oct-2015 - The fight between CROs for clinical research associates (CRAs) and people with certain other skillsets is hotting up, with both Icon and Quintiles identifying it as an issue faced by...

Russia's clinical trial approvals 'on the increase'

26-Oct-2015 - The number of clinical trials given the green light in Russia has increased 13% in the third quarter of the year, which could be thanks in part to a reduction...

Indian CMO latest acquisition in Recipharm's aggressive growth push

20-Oct-2015 - An agreement to buy Indian CMO Nitin boosts Recipharm’s presence in emerging markets and plays into its aggressive growth strategy, the firm says.

Dispatches from CPhI

EFCG: ‘API’ days for Europe as Big Pharma returns in search of quality

15-Oct-2015 - Big Pharma has returned to Europe for its API sourcing due to reasons of quality and reliability, according to the European Fine Chemicals Group (EFCG).

Can nuclear deal make Iran a contract manufacturing destination?

19-Aug-2015 - There’s little chance US companies will consider Iran as a venue for pharmaceutical contract manufacturing, even in the current era of limited détente between the two countries, experts say....

Biocon: IPO will evolve Syngene CRO into full manufacturing services firm

20-Jul-2015 - Indian CRO Syngene has received approval for its IPO prospectus paving the way to spin out from its parent company Biocon.

Marken ships trial supplies directly to patients in Korea as MERS tapers off

01-Jul-2015 - As the outbreak of Middle East Respiratory System (MERS) slows in South Korea, logistics supplier Marken has been granted government permission to deliver the first direct to patient (DTP) shipments...

Quintiles maintains 'outperform' rating following recent flurry of activity

25-May-2015 - A recent spate of activity - including the acquisition of a Japanese CRO and a secondary equity offering - has boosted Quintiles’ investment appeal, an analyst says.

Tigermed Envy? WuXi may be eyeing a launch on Shenzhen exchange

14-May-2015 - With WuXi pushing full steam ahead in its bid to go private, one expert says that the company may be envious of a competing CRO -- Hangzhou Tigermed, which is...

Chinese drugmaker looks West in market expansion deal with ELC Group

22-Apr-2015 - Understanding international regulatory demands, manufacturing standards and overcoming cultural barriers are key for Asian drugmakers looking to enter Western markets, says market access CRO ELC Group.

Quintiles pushes further into LatAm with Argentinian hospital alliance

17-Apr-2015 - Quintiles on Thursday announced the selection of Hospital Italiano of Buenos Aires, Argentina, as the company’s first “Prime Site” in Latin America, adding to the company’s network of investigative sites...

WuXi offers more details on the complexity of CRO, CMO competition

15-Apr-2015 - Competition in the notoriously tight-lipped CRO (contract research organization) and CMO (contract manufacturing organization) industries is getting fiercer as outsourcing picks up, though that hasn’t stopped one Chinese company from...

'Unjustified' ban of GVK-tested drugs has damaged India, says Pharmexcil

08-Apr-2015 - The reputation of Indian clinical trials has been damaged by the “unjustified” suspension of medicines tested by GVK Biosciences, Pharmexcil says as it attacks the evidence submitted by French regulators.

AMRI sets sights on acquiring Indian API manufacturer, CEO says

11-Mar-2015 - Following its three acquisitions over the last year, AMRI is now looking to extend its footprint into India further with the acquisition of a FDA-approved API site, William Marth, president...

Key Industry Events


Access all events listing

Our events, Shows & Conferences...